# Advanced Immunological Approach in COPD Exacerbation

> **NCT02417649** · PHASE4 · COMPLETED · sponsor: **Lallemand Pharma AG** · enrollment: 288 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Ismigen

## Key facts

- **NCT ID:** NCT02417649
- **Lead sponsor:** Lallemand Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 288 (ACTUAL)
- **Last updated:** 2015-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02417649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02417649, "Advanced Immunological Approach in COPD Exacerbation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02417649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*